Interferon alfa treatment for Sjogren's syndrome associated neuropathy.
Treatment response to interferon alfa (IFNalpha) is described in three consecutive cases of two forms of Sjogren's syndrome associated neuropathy (SSN)-two with sensory ataxic ganglionopathy and one with sensorimotor neuropathy with demyelinating features. All responded well to IFNalpha in terms of neuropathic symptoms, sicca symptoms, antibody titres, and findings in salivary gland biopsy specimens. IFNalpha thus showed promise in treating both SSN and the underlying Sjogren's syndrome.
Yamada
S
S
Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya 466-8550, Japan.
Mori
K
K
Matsuo
K
K
Inukai
A
A
Kawagashira
Y
Y
Sobue
G
G
D000368:Aged; D000906:Antibodies / Q000276:immunology; D001479:Basal Ganglia / Q000473:pathology; D001706:Biopsy; D003711:Demyelinating Diseases / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005073:Evoked Potentials, Somatosensory / Q000502:physiology; D005260:Female; D020234:Gait Ataxia / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000502:physiology; D010292:Paresthesia / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D012469:Salivary Glands / Q000473:pathology; D012859:Sjogren's Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology
D000906:Antibodies; D007155:Immunologic Factors; D016898:Interferon-alpha